ArticleScientific reports2025
The developing role of NRF2 and HMOX1 in treatment response of cutaneous leishmaniasis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Anthroponotic cutaneous leishmaniasis (ACL), a neglected parasitic disease, created significant treatment challenges due to rising antimonial resistance, particularly in endemic regions like Iran. This study aimed to investigate the mechanisms behind treatment unresponsiveness in ACL patients. Demographic and clinical characteristics of 21 unresponsive and 10 responsive patients were randomly collected. Leishmania isolates were genotyped using nested polymerase chain reaction (PCR). Real-time PCR assessed the expression levels of two key genes related to treatment unresponsiveness: nuclear factor erythroid 2-related factor 2 (NRF2) and heme oxygenase 1 (HMOX1), along with their associated microRNAs, mir-24a-3p and mir-27b-3p. Gene expression and immunohistochemistry (IHC) assays measured apoptosis activation. Unresponsive patients revealed decreased expression of apoptosis-related genes (Bax, caspase-3, caspase-8) and increased expression of B-cell lymphoma 2 (Bcl2). Furthermore, HMOX1 and NRF2 expression, significant mir-27b-3p upregulation, and mir-24a-3p downregulation were observed in the unresponsive group. These results suggest diminished apoptosis and/or possible potential for chronic progression of Leishmania (L.) tropica infection in unresponsive patients. The increased levels of NRF2 and HMOX1 demonstrate their probable role in drug unresponsiveness. Also, the opposing effects of mir-24a-3p and mir-27b-3p on mentioned genes highlight the necessity for targeted molecular studies to modulate microRNAs expression effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.